Urogen Pharma Ltd (URGN)

$14.3

+0.04

(+0.28%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Urogen Pharma Ltd

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 20.85M → 23.53M (in $), with an average increase of 11.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.87M → -26.01M (in $), with an average decrease of 18.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.8% return, outperforming this stock by 36.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 229.2% return, outperforming this stock by 255.7%

Performance

  • $14.15
    $14.67
    $14.30
    downward going graph

    1.05%

    Downside

    Day's Volatility :3.54%

    Upside

    2.52%

    downward going graph
  • $8.69
    $24.13
    $14.30
    downward going graph

    39.23%

    Downside

    52 Weeks Volatility :63.99%

    Upside

    40.74%

    downward going graph

Returns

PeriodUrogen Pharma LtdSector (Health Care)Index (Russel 2000)
3 Months
-10.82%
-1.1%
0.0%
6 Months
23.25%
10.3%
0.0%
1 Year
11.41%
5.3%
1.7%
3 Years
-26.53%
14.5%
-22.3%

Highlights

Market Capitalization
472.9M
Book Value
- $2.01
Earnings Per Share (EPS)
-3.55
PEG Ratio
0.0
Wall Street Target Price
38.5
Profit Margin
-123.61%
Operating Margin TTM
-62.09%
Return On Assets TTM
-26.1%
Return On Equity TTM
-1481.26%
Revenue TTM
82.7M
Revenue Per Share TTM
2.87
Quarterly Revenue Growth YOY
30.099999999999998%
Gross Profit TTM
56.7M
EBITDA
-64.7M
Diluted Eps TTM
-3.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.62
EPS Estimate Next Year
-2.36
EPS Estimate Current Quarter
-0.68
EPS Estimate Next Quarter
-0.73

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Urogen Pharma Ltd(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 169.23%

Current $14.30
Target $38.50

Company Financials

FY18Y/Y Change
Revenue
1.1M
↓ 86.17%
Net Income
-75.7M
↑ 278.28%
Net Profit Margin
-6.7K%
↓ 6462.02%
FY19Y/Y Change
Revenue
18.0K
↓ 98.4%
Net Income
-100.5M
↑ 32.88%
Net Profit Margin
-558.5K%
↓ 551792.82%
FY20Y/Y Change
Revenue
11.8M
↑ 65450.0%
Net Income
-128.5M
↑ 27.81%
Net Profit Margin
-1.1K%
↑ 557411.06%
FY21Y/Y Change
Revenue
48.0M
↑ 307.17%
Net Income
-110.8M
↓ 13.75%
Net Profit Margin
-230.67%
↑ 858.27%
FY22Y/Y Change
Revenue
64.4M
↑ 33.96%
Net Income
-109.2M
↓ 1.5%
Net Profit Margin
-169.62%
↑ 61.05%
FY23Y/Y Change
Revenue
82.7M
↑ 28.52%
Net Income
-102.2M
↓ 6.34%
Net Profit Margin
-123.61%
↑ 46.01%
Q3 FY22Q/Q Change
Revenue
16.1M
↓ 3.05%
Net Income
-25.8M
↓ 3.22%
Net Profit Margin
-160.47%
↑ 0.28%
Q4 FY22Q/Q Change
Revenue
18.1M
↑ 12.39%
Net Income
-28.2M
↑ 9.36%
Net Profit Margin
-156.14%
↑ 4.33%
Q1 FY23Q/Q Change
Revenue
17.2M
↓ 4.97%
Net Income
-30.2M
↑ 6.95%
Net Profit Margin
-175.74%
↓ 19.6%
Q2 FY23Q/Q Change
Revenue
21.1M
↑ 22.96%
Net Income
-24.1M
↓ 20.11%
Net Profit Margin
-114.18%
↑ 61.56%
Q3 FY23Q/Q Change
Revenue
20.9M
↓ 1.36%
Net Income
-21.9M
↓ 9.35%
Net Profit Margin
-104.93%
↑ 9.25%
Q4 FY23Q/Q Change
Revenue
23.5M
↑ 12.84%
Net Income
-26.0M
↑ 18.91%
Net Profit Margin
-110.57%
↓ 5.64%
FY18Y/Y Change
Total Assets
103.6M
↑ 37.07%
Total Liabilities
13.5M
↑ 91.4%
FY19Y/Y Change
Total Assets
202.4M
↑ 95.43%
Total Liabilities
22.1M
↑ 64.03%
FY20Y/Y Change
Total Assets
122.0M
↓ 39.72%
Total Liabilities
25.7M
↑ 16.14%
FY21Y/Y Change
Total Assets
119.7M
↓ 1.85%
Total Liabilities
111.3M
↑ 334.05%
FY22Y/Y Change
Total Assets
136.2M
↑ 13.77%
Total Liabilities
225.0M
↑ 102.08%
FY23Y/Y Change
Total Assets
178.3M
↑ 30.88%
Total Liabilities
243.5M
↑ 8.24%
Q3 FY22Q/Q Change
Total Assets
128.5M
↓ 12.09%
Total Liabilities
191.8M
↑ 2.52%
Q4 FY22Q/Q Change
Total Assets
136.2M
↑ 6.04%
Total Liabilities
225.0M
↑ 17.32%
Q1 FY23Q/Q Change
Total Assets
113.0M
↓ 17.09%
Total Liabilities
229.5M
↑ 2.01%
Q2 FY23Q/Q Change
Total Assets
95.4M
↓ 15.58%
Total Liabilities
233.8M
↑ 1.87%
Q3 FY23Q/Q Change
Total Assets
193.6M
↑ 103.05%
Total Liabilities
235.6M
↑ 0.78%
Q4 FY23Q/Q Change
Total Assets
178.3M
↓ 7.91%
Total Liabilities
243.5M
↑ 3.35%
FY18Y/Y Change
Operating Cash Flow
-37.3M
↑ 290.07%
Investing Cash Flow
35.3M
↓ 197.27%
Financing Cash Flow
66.4M
↑ 7.85%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 90.22%
Investing Cash Flow
-145.6M
↓ 512.6%
Financing Cash Flow
165.3M
↑ 148.79%
FY20Y/Y Change
Operating Cash Flow
-105.9M
↑ 49.1%
Investing Cash Flow
93.2M
↓ 164.04%
Financing Cash Flow
16.5M
↓ 90.0%
FY21Y/Y Change
Operating Cash Flow
-84.9M
↓ 19.83%
Investing Cash Flow
4.1M
↓ 95.64%
Financing Cash Flow
72.3M
↑ 337.58%
FY22Y/Y Change
Operating Cash Flow
-87.6M
↑ 3.14%
Investing Cash Flow
1.1M
↓ 73.95%
Financing Cash Flow
97.1M
↑ 34.31%
Q3 FY22Q/Q Change
Operating Cash Flow
-17.6M
↓ 27.22%
Investing Cash Flow
-35.5M
↑ 23405.3%
Financing Cash Flow
1.1M
↓ 1529.87%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.8M
↑ 23.51%
Investing Cash Flow
23.1M
↓ 165.11%
Financing Cash Flow
25.4M
↑ 2204.09%
Q1 FY23Q/Q Change
Operating Cash Flow
-25.8M
↑ 18.64%
Investing Cash Flow
6.3M
↓ 72.87%
Financing Cash Flow
671.0K
↓ 97.35%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.3M
↓ 21.44%
Investing Cash Flow
3.7M
↓ 40.67%
Financing Cash Flow
143.0K
↓ 78.69%

Technicals Summary

Sell

Neutral

Buy

Urogen Pharma Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Urogen Pharma Ltd
Urogen Pharma Ltd
4.39%
23.25%
11.41%
-26.53%
-60.79%
Moderna, Inc.
Moderna, Inc.
24.09%
61.99%
-3.5%
-32.49%
361.73%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.4%
14.78%
16.74%
91.89%
178.31%
Novo Nordisk A/s
Novo Nordisk A/s
-2.34%
26.33%
47.85%
229.23%
422.3%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.12%
6.37%
15.53%
83.6%
130.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Urogen Pharma Ltd
Urogen Pharma Ltd
NA
NA
0.0
-3.62
-14.81
-0.26
NA
-2.01
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Urogen Pharma Ltd
Urogen Pharma Ltd
Buy
$472.9M
-60.79%
NA
-123.61%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
361.73%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
178.31%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
422.3%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.15%
28.81
36.68%

Institutional Holdings

    Corporate Announcements

    • Urogen Pharma Ltd Earnings

      Urogen Pharma Ltd’s price-to-earnings ratio stands at None

      Read More

    Company Information

    urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.

    Organization
    Urogen Pharma Ltd
    Employees
    198
    CEO
    Ms. Elizabeth A. Barrett
    Industry
    Health Technology

    Discover More

    FAQs